TNFRSF8 and non-Hodgkin lymphoma: Beyond the direct activity against CD30+ NHL, BV combined therapy with rituximab, a CD20-targeted agents, produce robust clinical response in large B-cell lymphoma regardless of CD30 expression (45, 46), suggesting a potential synergistic antitumor effects with CD20/CD30 dual targeting therapies.